N/A
N=40
Effectiveness of Subcutaneous Glargine On The Time To Closure of The Anion Gap in Patients Presenting to the Emergency Department With Diabetic Keto-acidosis
Diabetic Ketoacidosis
Bottom Line
View on ClinicalTrials.gov: NCT02006342 ↗Enrolled (actual)
40
Serious AEs
0.0%
Results posted
May 2017
Primary outcome: Primary: Time to Anion Gap Closure — 10.2; 11.6 hours
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Insulin Glargine (Drug); Regular Insulin (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- The University of Texas Health Science Center, Houston
- Primary completion
- Apr 2013
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Time to Anion Gap Closure |
10.2; 11.6 | — |
| SECONDARY Number of Participants Admitted to the ICU |
6; 4 | — |
| SECONDARY Intensive Care Unit Length of Stay |
1.8; 1.2 | — |
| SECONDARY Hospital Length of Stay |
3.9; 4.6 | — |
| SECONDARY Number of Participants Who Developed Hypoglycemia |
2; 3 | — |
Summary
To determine if co-administration of subcutaneous (SQ)Insulin glargine in combination with intravenous (IV) insulin decreases the time to resolution of ketoacidosis and requirement for ICU admission compared to IV insulin with delayed administration of SQ glargine for the treatment of diabetic ketoacidosis (DKA).
Eligibility Criteria
Inclusion Criteria
- Age >18 years
- Blood Glucose >200
- potential of hydrogen (pH) or = 16
Exclusion Criteria
- Age < 18 years
- Pregnant
- End state renal disease (ESRD)
- Prisoners
- Patients in shock or requiring emergency surgery
- Those unwilling to consent for the trial
- Allergic to Insulin Glargine
Data sourced from ClinicalTrials.gov (NCT02006342). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.